Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apellis Pharmaceuticals, Inc. (APLS) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical issuer listed on the Nasdaq Global Select Market, Apellis uses filings such as Forms 10-K, 10-Q, 8-K, and others to report on its business, financial condition, risk factors, and material events related to its complement-based therapies SYFOVRE and EMPAVELI/Aspaveli.
In these filings, investors can review detailed information on revenue from SYFOVRE and EMPAVELI, research and development spending for ophthalmology and rare disease programs, and the status of key clinical trials such as GALE and VALIANT. Risk factor and management discussion sections typically describe the scientific and regulatory considerations associated with targeting C3 in geographic atrophy, C3 glomerulopathy, primary IC-MPGN, and paroxysmal nocturnal hemoglobinuria.
Current reports on Form 8-K, such as the Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Sobi), document material definitive agreements that affect Apellis’ economics, including ex-U.S. royalty structures for Aspaveli and related financing consents. These filings help clarify how collaborations and capital arrangements support the company’s commercialization and pipeline strategy.
On Stock Titan, Apellis filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly understand topics like royalty arrangements, cash runway, product revenue trends, and major clinical or regulatory milestones. Users can also review Forms 4 and other insider transaction reports to monitor trading activity by Apellis directors and executives, alongside proxy and governance disclosures that describe compensation and board oversight. This page is a central resource for analyzing the regulatory record behind APLS stock.
Apellis Pharmaceuticals insider plans to sell additional shares under Rule 144. A notice was filed for the proposed sale of 3,371 shares of Apellis common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 73,371.17 and 126,525,218 shares outstanding.
The shares to be sold were acquired on 01/21/2026 through restricted stock vesting from the issuer as compensation. In the past three months, Mark J. Delong has already sold 1,780 shares for 39,493.22 on 01/13/2026 and 1,334 shares for 26,403.73 on 01/20/2026. By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about Apellis.
APLS insider plans a new stock sale under Rule 144. A notice was filed to sell 27,192 shares of common stock through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 01/22/2026. The filing lists an aggregate market value of 591,844.76 for these shares and notes that 126,525,218 common shares are outstanding.
The 27,192 shares to be sold were acquired on 01/21/2026 through restricted stock vesting from the issuer as compensation, with payment also dated 01/21/2026. The notice also reports prior sales over the past three months by Cedric Francois at the same address, including 10,186 common shares sold on 01/13/2026 for gross proceeds of 225,998.82 and 8,182 common shares sold on 01/20/2026 for gross proceeds of 161,945.51. The signer represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
APLS shareholder Nur Nicholson has filed a Rule 144 notice to sell 7,725 shares of common stock. The shares are to be sold through Fidelity Brokerage Services on the NASDAQ exchange, with an aggregate market value of $168,137.72 based on the figures in the notice. The filing lists 126,525,218 common shares outstanding and targets an approximate sale date of January 22, 2026.
The 7,725 shares were acquired on January 21, 2026 through restricted stock vesting from the issuer as compensation. The notice also shows that over the prior three months, Nicholson sold 2,618 and 2,203 common shares on January 13 and January 20, 2026, for gross proceeds of $58,086.09 and $43,603.76, respectively. The signer represents they are not aware of undisclosed material adverse information about the issuer’s operations.
A shareholder has filed a notice of intent to sell common stock under Rule 144. The filing covers the planned sale of 2,064 common shares through Fidelity Brokerage Services LLC on or about 01/22/2026, to be traded on NASDAQ at an aggregate market value of $44,923.79.
The 2,064 shares were acquired on 01/21/2026 via restricted stock vesting from the issuer as compensation. The notice also lists prior sales by James G. Chopas over the past three months, including 873 common shares sold on 01/13/2026 for $19,369.43 and 726 common shares sold on 01/20/2026 for $14,369.65.
A Form 144 notice indicates that Caroline R. Baumal plans to sell up to 2,797 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $60,877.82. These shares relate to restricted stock that vested on 01/21/2026 and were acquired from the issuer as compensation.
The planned sale is expected to occur around 01/22/2026 on the NASDAQ, and the filing notes that 126,525,218 shares of this class were outstanding. In the prior three months, Baumal sold additional common shares in two transactions totaling 4,902 shares, for gross proceeds of $77,096.67 and $37,250.24, respectively. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
Apellis Pharmaceuticals Chief Medical Officer Caroline Baumal reported a routine share sale related to tax withholding. On January 20, 2026, she sold 1,882 shares of Apellis common stock at a price of $19.7929 per share. According to the footnote, this sale was made to cover tax withholding on Restricted Stock Units that were released on January 16, 2026.
After this transaction, Baumal beneficially owned 89,324 shares of Apellis common stock in direct ownership form. The filing indicates this was a single non-derivative transaction coded as a sale, tied specifically to the vesting of equity compensation rather than an open-market discretionary sale.
Apellis Pharmaceuticals VP/Chief Accounting Officer James George Chopas reported a small sale of company stock in connection with equity compensation. On January 20, 2026, he sold 726 shares of Apellis common stock at a price of $19.7929 per share. According to the filing, these shares were sold to cover tax withholding on restricted stock units that were released on January 16, 2026.
After this transaction, Chopas beneficially owned 51,869 shares of Apellis common stock in direct ownership. The filing indicates the transaction was a routine tax-related sale rather than an open-market discretionary reduction of his overall stake.
Apellis Pharmaceuticals Chief Business & Strat Officer Mark Jeffrey DeLong reported a small stock sale related to tax withholding. On January 20, 2026, he sold 1,334 shares of Apellis common stock at an average price of $19.7929 per share, coded as a sale transaction.
According to the filing, this sale represents shares sold to cover tax withholding on restricted stock units that were released on January 16, 2026. After this transaction, DeLong directly owns 81,724 shares of Apellis common stock.
Apellis Pharmaceuticals Chief Scientific Officer Pascal Deschatelets reported a small share sale related to tax withholding. On January 20, 2026, he sold 909 shares of Apellis common stock at an average price of $19.7929 per share. The filing explains that these shares were sold to cover taxes due on Restricted Stock Units that vested on January 16, 2026.
After this transaction, Deschatelets beneficially owned 1,157,310 shares of Apellis common stock in direct form. The transaction is reported on a Form 4 as a non-derivative disposition coded "S," indicating an open-market or similar sale.
Apellis Pharmaceuticals, Inc. Chief Executive Officer and director Cedric Francois reported a sale of common stock mainly tied to taxes on equity compensation. On January 20, 2026, he sold 8,182 shares of Apellis common stock at $19.7929 per share, in a transaction described as covering tax withholding on restricted stock units that were released on January 16, 2026. Following this sale, he directly owned 313,237 shares of common stock.
In addition to his direct holdings, the filing lists several indirect holdings through trusts, including 307,946 shares held by The Cedric Francois Irrevocable Trust of 2023 - 2, 472,065 shares held by The Cedric Francois Irrevocable Trust of 2023, 300,000 shares held by The Francois Grossi Trust, and 234,411 shares held by The Francois-DuBois Educational Trust. The filing states that Francois disclaims beneficial ownership of shares held in these trusts except to the extent of his pecuniary interest.